We are pleased to share the news that Strensiq™ (asfotase alfa) has been approved by the U.S. Food and Drug Administration (FDA). Strensiq is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). Strensiq is the first and only approved therapy for patients with this devastating, ultra-rare metabolic disease.
Today’s approval is a long-awaited milestone for HPP patients and their families, many of whom faced the serious complications of HPP without the benefit of an effective treatment option. Alexion is pleased to make Strensiq available to HPP patients in the United States.
As part of our commitment to the HPP community, Alexion offers OneSource™, a comprehensive program that pairs each HPP patient and family with a dedicated Alexion Nurse Case Manager who will be a resource for disease education and treatment support. Patients and caregivers can call 888-765-4747 to speak with an Alexion Nurse Case Manager and learn about support options.
Full prescribing information for Strensiq is available at http://alexion.com/Documents/strensiq_pi-10-2015.